NephCure Kidney International ®

Saving Kidneys, Saving Lives

AURONA

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (AURONA)

This study will evaluate the safety and efficacy, measured by reaching complete or partial remission, of voclosporin for FSGS patients. The aim of this trial is to assess the efficacy of voclosporin (VCS) (a softgel capsule) in achieving complete or partial remission of proteinuria after 24 weeks of therapy in patients with focal segmental glomerulosclerosis (FSGS). Also, the team will assess the safety and tolerability of VCS over 24 weeks.

How To Contact a Study Center:

Our Mission

NephCure Kidney International’s ® mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases.

Sign up for our emails »

Contact Information

150 S. Warner Road
Suite 402
King of Prussia, PA 19406
1.866 NephCure (637-4287)
info@nephcure.org
EIN: 38-3569922

© Copyright 2021 NephCure Kidney International, Inc. All rights reserved worldwide. NephCure Kidney International, and the logo, are federally registered trademarks of NephCure Kidney International, Inc.